CSIMarket Company Name, Ticker, Customers, else..
 
Kazia Therapeutics Limited  (NASDAQ: KZIA)
 
Price: $11.0650 $0.05 0.500%
Day's High: $11.25 Week Perf: -10.11 %
Day's Low: $ 10.84 30 Day Perf: -13.49 %
Volume (M): 142,992 52 Wk High: $ 17.40
Volume (M$): $ 0 52 Wk Avg: $9.95
Open: $11.10 52 Wk Low: $4.86



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 47
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -21
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Kazia Therapeutics Limited is a global biotechnology company that specializes in the development of innovative cancer therapies. Founded in 2015, the company focuses on discovering and commercializing novel drugs to target difficult-to-treat cancers. Kazia Therapeutics is known for its lead drug candidate, paxalisib (formerly GDC-0084), which is being developed as a potential treatment for glioblastoma, a highly aggressive form of brain cancer. The company works closely with leading research institutions and healthcare providers to advance its pipeline of drug candidates and improve patient outcomes. Kazia Therapeutics is headquartered in Sydney, Australia, with operations and collaborations spanning across the United States and Europe.


   Company Address: Three International Towers, Level 24, 300 Barangaroo Avenue Sydney 2000
   Company Phone Number: 9472-4101   Stock Exchange / Ticker: NASDAQ KZIA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADCT   -20.08%    
KPTI   -25.99%    
RYTM   -0.79%    
SUPN   -4.5%    
YMAB        0.35% 
ZYME   -12.04%    
• View Complete Report
   





Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.31
Working Capital Ratio 0.35
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 0 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash -
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 894
Net Income per Employee (TTM) -440,468
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.01

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -38104.76 %
Net Margin (MRQ) -49290.48 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Kazia Therapeutics Limited's Segments
Sale of paxalisib    100 % of total Revenue
Sale of paxalisib Timing of revenue recognition    100 % of total Revenue
Israel    100 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.